Entering text into the input field will update the search result below

Enrollment underway in Eli Lilly' Emgality vs. Nurtec ODT trial in migraine

Woman with a headache

yamasan/iStock via Getty Images

  • Eli Lilly (NYSE:LLY) announces that enrollment is now open for the CHALLENGE-MIG clinical trial, the first and only head-to-head trial comparing two anti-calcitonin gene-related peptide (CGRP) medicines for the preventive treatment of episodic migraine in adults.

Recommended For You

More Trending News

About LLY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
LLY--
Eli Lilly and Company